[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE534386T1 - Antikrebs-zusammensetzung mit prolin bzw. prolinderivaten und einem antitumorantikörper - Google Patents

Antikrebs-zusammensetzung mit prolin bzw. prolinderivaten und einem antitumorantikörper

Info

Publication number
ATE534386T1
ATE534386T1 AT05770217T AT05770217T ATE534386T1 AT E534386 T1 ATE534386 T1 AT E534386T1 AT 05770217 T AT05770217 T AT 05770217T AT 05770217 T AT05770217 T AT 05770217T AT E534386 T1 ATE534386 T1 AT E534386T1
Authority
AT
Austria
Prior art keywords
proline
derivatives
antitumorant
antibodies
cancer composition
Prior art date
Application number
AT05770217T
Other languages
English (en)
Inventor
Zoser B Salama
Original Assignee
Zoser B Salama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoser B Salama filed Critical Zoser B Salama
Application granted granted Critical
Publication of ATE534386T1 publication Critical patent/ATE534386T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05770217T 2004-06-14 2005-06-07 Antikrebs-zusammensetzung mit prolin bzw. prolinderivaten und einem antitumorantikörper ATE534386T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57883204P 2004-06-14 2004-06-14
PCT/EP2005/006184 WO2005120495A1 (en) 2004-06-14 2005-06-07 Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody

Publications (1)

Publication Number Publication Date
ATE534386T1 true ATE534386T1 (de) 2011-12-15

Family

ID=35064616

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05770217T ATE534386T1 (de) 2004-06-14 2005-06-07 Antikrebs-zusammensetzung mit prolin bzw. prolinderivaten und einem antitumorantikörper

Country Status (13)

Country Link
US (1) US7727530B2 (de)
EP (1) EP1765328B1 (de)
JP (1) JP2008502622A (de)
KR (1) KR20070026646A (de)
CN (1) CN1997365A (de)
AT (1) ATE534386T1 (de)
AU (1) AU2005251463A1 (de)
BR (1) BRPI0512040A (de)
CA (1) CA2568306A1 (de)
MX (1) MXPA06014731A (de)
RU (1) RU2007101074A (de)
WO (1) WO2005120495A1 (de)
ZA (1) ZA200700367B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY138883A (en) * 2000-08-29 2009-08-28 Government Of Malaysia As Represented By The Ministry Of Science Tehnology And Innovation Malaysia Use of asiatic acid for treatment of cencer
MXPA04008253A (es) 2002-02-25 2005-04-19 Diffusion Pharmaceuticals Llc Sales de carotenoides trans bipolares y sus usos.
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
EP2540696B1 (de) 2005-02-24 2020-01-01 Diffusion Pharmaceuticals LLC Trans-Karotinoide, deren Formulierung und Verwendung
AU2008246305B2 (en) 2007-04-13 2013-03-21 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
US8206751B2 (en) 2007-10-31 2012-06-26 Diffusion Pharmaceuticals Llc Class of therapeutics that enhance small molecule diffusion
CN108464976A (zh) 2009-06-22 2018-08-31 扩散药品有限公司 扩散促进化合物及其单独或与溶栓药一起的应用
CN103038644B (zh) * 2010-06-01 2016-03-09 梅坦诺米克斯保健有限公司 用于在受试者中诊断胰腺癌的工具和方法
ES2654945T3 (es) 2010-06-02 2018-02-15 Diffusion Pharmaceuticals Llc Formulaciones orales de carotenoides trans bipolares
CN109152839A (zh) 2016-03-24 2019-01-04 扩散药品有限公司 双极性反式类胡萝卜素连同化疗和放射治疗在治疗癌症中的用途
KR102012554B1 (ko) * 2016-07-13 2019-08-23 주식회사 노브메타파마 사이클로 히스티딘-프롤린을 유효성분으로 포함하는 세포 보호용 조성물
CN114028388B (zh) * 2021-12-16 2023-05-12 郑州大学第一附属医院 脯氨酸在制备肺癌治疗药物中的应用
CN116092631A (zh) * 2023-01-17 2023-05-09 湖南安泰康成生物科技有限公司 铁死亡诱导剂与电场联用的肿瘤治疗系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US6153643A (en) * 1984-11-05 2000-11-28 Hoerrmann; Wilhelm Anti-cancer-substance
CA1281288C (en) * 1984-11-05 1991-03-12 Wilhelm Hoerrmann Tumor therapy
US5665371A (en) * 1985-05-20 1997-09-09 Hoerrmann; Wilhelm Medicines which contain derivatives of proline or hydroxyproline
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
DE10359828A1 (de) 2003-12-12 2005-07-28 Zoser B. Dr.Rer.Nat. Salama CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe
WO2005058816A1 (de) * 2003-12-18 2005-06-30 Salama Zoser B Prolinderivate als pharmazeutische wirkstoffe in der tumortherapie

Also Published As

Publication number Publication date
JP2008502622A (ja) 2008-01-31
ZA200700367B (en) 2008-07-30
CN1997365A (zh) 2007-07-11
MXPA06014731A (es) 2007-04-25
US20050276810A1 (en) 2005-12-15
WO2005120495A1 (en) 2005-12-22
US7727530B2 (en) 2010-06-01
CA2568306A1 (en) 2005-12-22
AU2005251463A1 (en) 2005-12-22
EP1765328A1 (de) 2007-03-28
EP1765328B1 (de) 2011-11-23
RU2007101074A (ru) 2008-07-20
BRPI0512040A (pt) 2008-02-06
KR20070026646A (ko) 2007-03-08

Similar Documents

Publication Publication Date Title
ATE516819T1 (de) Verfahren zur behandlung von b-zell-bedingtem krebs
MX2018010331A (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos.
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
CY1109877T1 (el) Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
CO6150193A2 (es) Terapia tumoral con anticuerpo anti-vegf
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
EA202091514A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR
ATE534386T1 (de) Antikrebs-zusammensetzung mit prolin bzw. prolinderivaten und einem antitumorantikörper
BRPI0711908B8 (pt) anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo.
IN2015KN00350A (de)
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
UA94899C2 (ru) Фиксированное дозирование антител к her
CO6620013A2 (es) Anticuerpos hacia gdf8 humano
UA117294C2 (uk) Імунокон'югат
NO20080012L (no) Fremgangsmater for behandling av hjernetumorer med antistoffer
MY151449A (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
RU2012140185A (ru) Ингибирование ангиогенеза
EA201270124A1 (ru) Новые терапевтические и диагностические средства
EA202090640A1 (ru) Получение твердых лекарственных форм, содержащих антитела, путем наслаивания раствора/суспензии
EP3991749A3 (de) Therapeutikum für einen tumor mit einem ido-hemmer in kombination mit einem antikörper
DE60311788D1 (de) Kombinationstherapie zur behandlung von krebs